Boehringer Ingelheim and Envisagenics have launched a multi-year oncology collaboration to use AI and transcriptomics to identify tumour-specific targets created by alternative RNA splicing, tapping what the companies describe as a largely unexplored source of cancer drug targets. Envisagenics says its SpliceCore database includes more than 14 million RNA-splicing events, and the deal could bring the biotech over $1 billion as Boehringer looks for medicines for hard-to-treat solid tumours.

Why It Matters To Oncology

• Alternative RNA splicing can generate tumour-specific protein isoforms that may be invisible to conventional gene-centric discovery approaches.

• That could expand the target pool for clinicians and drug developers seeking more selective therapies in solid tumours.

• Boehringer said it may pursue validated targets with modalities including antibody-drug conjugates, T-cell engagers and multispecific antibodies.

The Financials

• Envisagenics could receive more than $1 billion through upfront payment, research funding, option fees, and development, regulatory and commercial milestones.

• The biotech is also eligible for royalties on future product sales.

• Boehringer will hold options to exclusively license selected targets for development and commercialization.

What They're Saying

• Envisagenics CEO Maria Luisa Pineda called cancer-associated splicing changes “one of the richest untapped sources of novel disease-specific therapeutic targets across human disease.”

• Boehringer oncology research head Mark Petronczki said alternative RNA splicing offers access to a “largely unexplored target space.”

• The pitch: pair Envisagenics’ AI-powered SpliceCore platform with Boehringer’s oncology development capabilities.

What's Next

• The partners will screen for tumour-specific splicing-derived targets and assess whether selected candidates can be translated into drugs for hard-to-treat solid tumours.

• If targets are validated, Boehringer can opt into exclusive licenses and advance them across multiple therapeutic modalities.

• The collaboration also adds to Envisagenics’ growing pharma roster, following prior work with Biogen, Johnson & Johnson and Bristol Myers Squibb.